加用文拉法辛缓释剂对纤维肌痛病人疼痛和生活质量的影响

Effects of venlafaxine extended release on pain and lift quality in patients with fibromyalgia syndrome

目的:评价文拉法辛缓释剂治疗纤维肌痛综合征的疗效和安全性。方法:采用病例对照研究,测查一般资料、心理症状自评量表(SCL-90)、健康状况调查问卷(SF-36)、视觉疼痛模拟量表(VAS)、5点口述疼痛评分问卷(VRS-5)和不良反应评定量表(TESS)。对74例纤维肌痛综合征病人进行12 wk治疗研究,按自愿原则分为2组:研究组38例,给予文拉法辛缓释剂联合常规治疗[即服用镇痛药(非甾体类抗炎镇痛药)];对照组36例,只给予常规治疗。结果:治疗wk 12,研究组VAS疼痛分(26±s 21)、VRS-5疼痛分(1.7±1.5),与对照组比较有非常显著差异(P<0.01);研究组SCL-90中躯体化、抑郁、敌对、恐怖与对照组比较有显著差异(P<0.05);SF-36问卷中生理机能、躯体疼痛、精力活力、一般健康状况、社会功能、情感职能和精神健康7个领域,研究组与对照组比较有显著差异(P<0.05或P<0.01)。研究组不良反应程度较轻微。结论:文拉法辛缓释剂是治疗纤维肌痛安全、有效的药物。

AIM： To evaluate the efficacy and safety of venlafaxine extended release （XR） in patients with fibromyalgia syndrome. METHODS： Seventy-four outpatients and inpatients with fibromyalgia syndrome were voluntarily assigned to two groups： the study group （treated with venlafaxine, n= 38） and the control group （only treated as routine, n= 36）. The effects and adverse reactions assessed by symptom checklist 90 （SCL-90）, short form 36 health survey questionnaire （SF-36）, the visual analogue scale （VAS）, a five-point verbal rating scale （VRS） and treatment emergent side-effect scale （TESS） before treatment and at the end of wk 12 of the study, respectively. RESULTS ： At the end of the wk 12, there was significant reduction of VAS and VRS scores in both groups （P 〈 0.01）. There were significant differences in the factors of somatization, depression, hostile, horror in SCL-90 between the two groups （P 〈 0.05）. There were significantly differences in the factors of physical functioning, bodily pain, general health, vitality, social function, role emotional and mental health in SF-36 between the two groups （P 〈 0.05 were mild and tolerable. CONCLUSION： Venlafaxine is fibromyalgia syndrome. or P 〈 0.01）. The adverse reactions of venlafaxine safe, effective and well-tolerated in patients with